Companies › Shanghai Bovax Biotechnology
2 active drug programs in 4 registered trials: 2 Phase 3, 2 Phase 2; Oncology, Infectious disease; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recom 9-valent HPV recombinant vaccine targeting HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 | HPV6, HPV11, HPV16, HPV18, HPV31 | Phase 3 | Genital Wart; Cervical Cancer | Jul 2027 |
| 15-valent HPV Recombinant Vaccine (medium dose) HPV L1 virus-like particle vaccine (15 HPV types) | – | Phase 2 | HPV Infection | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06756269 | 15-valent HPV Recombinant Vaccine (medium dose) | Phase 2 | HPV Infection | Infectious disease | Oct 2025 |
| NCT06756269 | 15-valent HPV Recombinant Vaccine (medium dose) | Phase 2 | HPV Infection | Infectious disease | Oct 2025 |
| NCT06465914 | 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recom | Phase 3 | Genital Wart | Oncology | Jul 2027 |
| NCT04422366 | 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recom | Phase 3 | Cervical Cancer | Oncology | Sep 2027 |
Merck & Co. (MSD) Beijing Health Guard Biotechnology National Vaccine and Serum Institute, China
National Vaccine and Serum Institute, China Beijing Health Guard Biotechnology Shanghai Jiatan Pharmatech MAXVAX Biotechnology Limited Liability Company CellCentric
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.